DETAILED ACTION
Claims 1-24 are currently pending in the instant application. Claims 1, 2, 4, 8, 11-16, and 19 are rejected. Claims 3, 5, 9, and 10 are objected. Claims 6, 7, 17, and 20-24 are withdraw from consideration as being for non-elected subject matter.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Election/Restrictions
Applicant's election with traverse of group I and the species:
PNG
media_image1.png
116
416
media_image1.png
Greyscale
in the reply filed on 3 November 2025 has been previously acknowledged.
According to MPEP 803.02, the examiner has determined whether the elected species is allowable. Applicants’ elected species appears allowable. Therefore, the search and examination has been previously extended to the compounds of claim 5 which appear allowable and now further to the compounds of claims 3, 9, and 10 which also appear allowable, and further to the compound:
PNG
media_image2.png
100
360
media_image2.png
Greyscale
which is not allowable.
Claims 1-5, 8-16, 18, and 19 have been examined to the extent that they are readable on the elected embodiment, the elected species and the above mentioned compounds.
Claim Objections
Claims 3, 5, 9 and 10 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
Response to Amendment and Arguments
Applicant's amendment and arguments filed 16 February 2026 have been fully considered and entered into the instant application. Applicant’s amendment to claim 18 has overcome the 35 USC 112(b) rejection of claim 18. Applicant’s amendment to claim 1 to define X, Y and Z as:
PNG
media_image3.png
86
168
media_image3.png
Greyscale
wherein at least one of X, Y and Z is not H has overcome the 35 USC 102(a)(1) rejection of claims 1-3, 8, 10-16, and 19 as being anticipated by Registry No. 1706459-03-1 and anticipated by SID 271679499. Applicant’s amendment to claim 1 to define X, Y and Z as:
PNG
media_image3.png
86
168
media_image3.png
Greyscale
wherein at least one of X, Y, and Z is not H has overcome the 35 USC 102(a)(1) rejection of claims 1-4, 10-16 and 19 as being anticipated by Registry No. 2199395-95-2. The 35 USC 102(a)(1) rejection of claim 18 is overcome as claim 18 has been amended to list specific compounds, which do not include compound 1-3 or 1-4.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claim(s) 1, 2, 4, 8, 11-16, and 19 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by WO 2018/112204.
WO 2018/112204 discloses compounds of the formula I:
PNG
media_image4.png
156
284
media_image4.png
Greyscale
on page 1, pharmaceutical compositions, and methods of treatment of FASN-mediated disorders such as cancer and viral disorders.
WO 2018/112204 discloses the specific example 151 on page 171:
PNG
media_image5.png
136
734
media_image5.png
Greyscale
which has IC50 data present on page 98. Page 90 provides pharmaceutical compositions of the disclosed compounds in paragraphs [00296] to [00298] for example. The compound of example 151 corresponds to the instant formula (II):
PNG
media_image6.png
148
354
media_image6.png
Greyscale
, for example, wherein X is R1, which is D-E-G, wherein D is a bond, E is absent, and G is a heteroaryl; Y is H, Z is H; A is CR’R’; each R' is H; Ra is H; and B and B’ together form a heterocycle that is substituted by C(O)Q wherein Q is NHOH. The prior art compound of example 151 corresponds to instant claim 2 wherein A is CH2. The prior art compound of example 151 corresponds to instant claim 4 wherein X is R1 and R1 is G and G is heteroaryl. The prior art compound of example 151 corresponds to instant claim 8 wherein Y is G and G is H. The prior art compound of example 151 corresponds to instant claim 11 wherein G is heteroaryl. The prior art compound of example 151 corresponds to instant claim 12 wherein E is absent. The prior art compound of example 151 corresponds to instant claim 13 wherein Ra is H. The prior art compound of example 151 corresponds to instant claim 14 as R2 is not required to be on formula (II). The prior art compound of example 151 corresponds to instant claim 15 as R’ is H. The prior art compound of example 151 corresponds to instant claim 16 as R is not required to be on formula (II). The prior art compound of example 151 corresponds to instant claim 19 as WO 2018/112204 provides pharmaceutical compositions on page 1, and page 90.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA L ANDERSON whose telephone number is (571)272-0696. The examiner can normally be reached Monday-Friday from 6am-2pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format.
For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/REBECCA L ANDERSON/Primary Examiner, Art Unit 1626 ____________________ 29 April 2026
Rebecca Anderson
Primary Examiner
Art Unit 1626, Group 1620
Technology Center 1600
Prosecution Insights